319 related articles for article (PubMed ID: 37782145)
1. Safety and Glycemic Outcomes During the MiniMed
Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
[No Abstract] [Full Text] [Related]
2. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA
Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909
[No Abstract] [Full Text] [Related]
3. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
[No Abstract] [Full Text] [Related]
4. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial.
Garg SK; Grunberger G; Weinstock R; Lawson ML; Hirsch IB; DiMeglio LA; Pop-Busui R; Philis-Tsimikas A; Kipnes M; Liljenquist DR; Brazg RL; Kudva YC; Buckingham BA; McGill JB; Carlson AL; Criego AB; Christiansen MP; Kaiserman KB; Griffin KJ; Forlenza GP; Bode BW; Slover RH; Keiter A; Ling C; Marinos B; Cordero TL; Shin J; Lee SW; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Jan; 25(1):1-12. PubMed ID: 36472543
[No Abstract] [Full Text] [Related]
5. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.
Forlenza GP; Ekhlaspour L; DiMeglio LA; Fox LA; Rodriguez H; Shulman DI; Kaiserman KB; Liljenquist DR; Shin J; Lee SW; Buckingham BA
Pediatr Diabetes; 2022 May; 23(3):324-329. PubMed ID: 35001477
[TBL] [Abstract][Full Text] [Related]
6. Glycemic control during Ramadan fasting in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed‑loop system: A randomized controlled trial.
Elbarbary NS; Ismail EAR
Diabetes Res Clin Pract; 2022 Sep; 191():110045. PubMed ID: 35987309
[TBL] [Abstract][Full Text] [Related]
7. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
[TBL] [Abstract][Full Text] [Related]
8. Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus.
Pei Y; Ke W; Lu J; Lin Y; Zhang Z; Peng Y; Bi Y; Li Y; Hou J; Zhang X; Chen X; Treminio Y; Lee SW; Shin J; Rhinehart AS; Vigersky RA; Mu Y
Diabetes Technol Ther; 2023 Oct; 25(10):718-725. PubMed ID: 37578804
[No Abstract] [Full Text] [Related]
9. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
[No Abstract] [Full Text] [Related]
10. Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI).
Petrovski G; Al Khalaf F; Campbell J; Day E; Almajaly D; Hussain K; Pasha M; Umer F; Hamdan M; Khalifa A
BMC Endocr Disord; 2022 Mar; 22(1):80. PubMed ID: 35351095
[TBL] [Abstract][Full Text] [Related]
11. MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks.
Pulkkinen MA; Varimo TJ; Hakonen ET; Harsunen MH; Hyvönen ME; Janér JN; Kiiveri SM; Laakkonen HM; Laakso SM; Wehkalampi K; Hero MT; Miettinen PJ; Tuomaala AK
Diabetes Technol Ther; 2023 Feb; 25(2):100-107. PubMed ID: 36511831
[No Abstract] [Full Text] [Related]
12. Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
Castañeda J; Mathieu C; Aanstoot HJ; Arrieta A; Da Silva J; Shin J; Cohen O
Diabetes Obes Metab; 2022 Nov; 24(11):2212-2221. PubMed ID: 35791621
[TBL] [Abstract][Full Text] [Related]
13. Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users.
Silva JD; Lepore G; Battelino T; Arrieta A; Castañeda J; Grossman B; Shin J; Cohen O
Diabetes Technol Ther; 2022 Feb; 24(2):113-119. PubMed ID: 34524003
[No Abstract] [Full Text] [Related]
14. 12-Month Real-Life Efficacy of the MiniMed 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.
Lablanche S; Delagenière J; Jalbert M; Sonnet E; Benichou M; Arnold N; Spiteri A; Le Berre JP; Renard E; Chevalier N; Borot S; Bonnemaison E; Coffin C; Teissier MP; Benhamou PY; Borel JC; Penfornis A; Joubert M; Kessler L
Diabetes Technol Ther; 2024 Jun; 26(6):426-432. PubMed ID: 38236643
[No Abstract] [Full Text] [Related]
15. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.
Garg SK; Weinzimer SA; Tamborlane WV; Buckingham BA; Bode BW; Bailey TS; Brazg RL; Ilany J; Slover RH; Anderson SM; Bergenstal RM; Grosman B; Roy A; Cordero TL; Shin J; Lee SW; Kaufman FR
Diabetes Technol Ther; 2017 Mar; 19(3):155-163. PubMed ID: 28134564
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Monitoring.
Gros Herguido N; Amuedo S; Bellido V; López Gallardo G; Losada F; Pérez Morales A; Ruiz Trillo CA; Soto Moreno A
Diabetes Technol Ther; 2023 Feb; 25(2):151-156. PubMed ID: 36108305
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes.
Piccini B; Pessina B; Casalini E; Lenzi L; Toni S
Pediatr Diabetes; 2022 Dec; 23(8):1647-1655. PubMed ID: 36317539
[TBL] [Abstract][Full Text] [Related]
18. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
Benhalima K; Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C
Lancet Diabetes Endocrinol; 2024 Jun; 12(6):390-403. PubMed ID: 38697182
[TBL] [Abstract][Full Text] [Related]
19. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses.
Nimri R; Grosman B; Roy A; Nir J; Fisch Shvalb N; Kurtz N; Loewenthal N; Gillon-Keren M; Muller I; Atlas E; Phillip M
Diabetes Technol Ther; 2021 Apr; 23(4):268-276. PubMed ID: 33185480
[No Abstract] [Full Text] [Related]
20. One-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes.
Bassi M; Patti L; Silvestrini I; Strati MF; Ponzano M; Minuto N; Maggi D
Front Endocrinol (Lausanne); 2023; 14():1099024. PubMed ID: 36777356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
